Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 15/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19577498 | 0.96 | ATF4 (0.51) | ATF4SMN1; SMN2RAB9AALDH1A1PKM | |
| SCHEMBL21117001 | 0.92 | ATF4 (0.55) | ATF4SMN1; SMN2HTTNPC1 | |
| SCHEMBL22661762 | 0.85 | ATF4 (0.51) | ATF4 | |
| SCHEMBL19577378 | 0.85 | ATF4 (0.55) | ATF4 | |
| SCHEMBL30445912 | 0.85 | ATF4 (0.55) | ATF4 | |
| SCHEMBL24116954 | 0.85 | ATF4 (0.54) | ATF4RAB9AALDH1A1NPC1 | |
| SCHEMBL30445771 | 0.85 | ATF4 (0.54) | ATF4RAB9AALDH1A1NPC1 | |
| SCHEMBL20973797 | 0.85 | ATF4 (0.62) | ATF4SMN1; SMN2 | |
| SCHEMBL30026047 | 0.85 | ATF4 (0.62) | ATF4SMN1; SMN2 | |
| SCHEMBL30446131 | 0.85 | ATF4 (0.53) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-30 | — | — | US | disclosed |
| CN-112204006-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3704089-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3452453-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3704089-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2019-06-27 | — | — | US | disclosed |
| EP-3452453-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017193041-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017193041-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | ATF4 1/4885SMN1; SMN2 2486/4885RAB9A 2904/4885 |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885SMN1; SMN2 2486/4885RAB9A 2904/4885 |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885SMN1; SMN2 2486/4885RAB9A 2904/4885 |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885SMN1; SMN2 2486/4885RAB9A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.